✨ Your Portfolio is fetched and updated from zerodha.
Micro Pharmaceuticals

Kilitch Drugs (India) Ltd.

KILITCH

Get real time AI alerts about this company on your WhatsApp!
Market Cap
₹586 Cr.
P/E
21.24

Kilitch Drugs (India) Ltd.

  • Kilitch Drugs(India)
  • Shivalik Rasayan
  • Prevest Denpro

FAQs on Kilitch Drugs (India) Ltd. Shareprice

Kilitch Drugs(India) has given better returns compared to its competitors.
Kilitch Drugs(India) has grown at ~18.32% over the last 4yrs while peers have grown at a median rate of 6.6%

Kilitch Drugs(India) is not expensive.
Latest PE of Kilitch Drugs(India) is 20.92, while 3 year average PE is 37.94.
Also latest EV/EBITDA of Kilitch Drugs(India) is 19.84 while 3yr average is 26.74.

View FAQ's On Business

Growth Table

  • Kilitch Drugs (India) Ltd.
  • Shivalik Rasayan
  • Prevest Denpro

Balance Sheet

  • Kilitch Drugs (India) Ltd.
  • Shivalik Rasayan
  • Prevest Denpro

Balance Sheet Snapshot

No data available.

Fund Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end

Profit & Loss

  • Kilitch Drugs (India) Ltd.
  • Shivalik Rasayan
  • Prevest Denpro

Cash Flow

  • Kilitch Drugs (India) Ltd.
  • Shivalik Rasayan
  • Prevest Denpro

Cash Flow Analysis

  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.

Ratios

= Dominant Factor
  • Kilitch Drugs (India) Ltd.
  • Shivalik Rasayan
  • Prevest Denpro

Quarterly Results

  • Kilitch Drugs (India) Ltd.
  • Shivalik Rasayan
  • Prevest Denpro

Reverse DCF

locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF

FAQs on Kilitch Drugs (India) Ltd. Financials

Balance sheet of Kilitch Drugs(India) is strong.
It shouldn't have solvency or liquidity issues.

Yes, The net debt of Kilitch Drugs(India) is increasing.
Latest net debt of Kilitch Drugs(India) is ₹50.52 Crs as of Sep-25.
This is greater than Mar-25 when it was ₹29.78 Crs.

The profit is oscillating.
The profit of Kilitch Drugs(India) is ₹26.13 Crs for TTM, ₹26.7 Crs for Mar 2025 and ₹14.6 Crs for Mar 2024.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Kilitch Drugs(India) latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%

Companies resources are allocated to majorly unproductive assets like Capital Work in Progress

View FAQ's On Shareholding
Ideas Dashboard
Results
Timeline
Watchlist
Portfolio
Alerts
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech